Is Agentix Corp (OTC-AGTX) undervalued or overvalued?

The current fair value label suggests the stock is close to fair value: Fair.

How is the financial health of Agentix Corp?

The current financial health read for Agentix Corp (OTC-AGTX) is Weak. This should be reviewed alongside valuation, profitability, debt and cash-flow quality metrics.

Does Agentix Corp (OTC-AGTX) pay dividends?

Based on the current data, dividend yield is 0.0%.

What is the P/E ratio for Agentix Corp (OTC-AGTX)?

The current P/E ratio listed for Agentix Corp (OTC-AGTX) is -1.7x. Use it together with growth, margins and sector comparisons rather than as a standalone valuation signal.

What is the market capitalization of Agentix Corp?

The current market capitalization listed for Agentix Corp is 801.339 K.

What is the enterprise value of Agentix Corp?

The current enterprise value listed for Agentix Corp is 1.154 M. Enterprise value can provide a broader valuation view than market capitalization alone because it also considers net debt.

What is the ticker symbol for Agentix Corp?

The ticker symbol for Agentix Corp is OTC-AGTX, and the stock is listed on OTC Markets.

Where is Agentix Corp (OTC-AGTX) listed?

Agentix Corp (OTC-AGTX) is listed on OTC Markets.

What is the debt-to-total-capital ratio for Agentix Corp?

The current debt-to-total-capital ratio listed for Agentix Corp is 30.6%, which helps investors evaluate the company’s financing structure and leverage profile.

Agentix Corp (AGTX) Fair Value & Stock Analysis

Q: What is the fair value of Agentix Corp (OTC-AGTX) stock?

A fair value estimate for Agentix Corp (OTC-AGTX) is not currently available in the latest data file.

Q: What is the analyst price target for OTC-AGTX stock?

An analyst price target for Agentix Corp (OTC-AGTX) is not currently available in the latest data file.

Agentix Corp (AGTX)

Agentix Corp is a clinical-stage biotechnology company listed on OTC Markets under the ticker AGTX. The company is developing therapies aimed at metabolic diseases in the United States, with two lead programs: AGTX-2004, a peripherally acting CB1 receptor antagonist, and AGTX-2003, a peripherally acting CB1 receptor inverse agonist. Both candidates have shown activity in animal studies, including models relevant to obesity, type 2 diabetes, and non-alcoholic fatty liver disease. The company adopted the Agentix name in June 2019 after operating as FairWind Energy, Inc. Agentix Corp was founded in 2020 and is based in Dana Point, California.

Stock Summary Fair Value Profitability & Growth Quality & Risk Events & Dividends Technical Outlook FAQ

Jump between the core stock analysis sections, valuation data, fair value models, technical outlook, and FAQ.

Data update note: Fair value and stock analysis metrics are updated after regular market sessions when new data becomes available.

Ticker	Fair Value	Fair Value Upside/Downside	Fair Value Rating	Analyst Price Target	Analyst Target Upside/Downside	Analyst Target Rating	Overall Financial Health	Upcoming Dividend Ex-Date	Dividend Payment Date	Upcoming Dividend	Dividend Yield	Next Earnings Date	P/E Ratio	Price-to-Book Ratio	Price-to-Sales Ratio	Market Cap	Enterprise Value	Total Debt / Total Capital	Free Float / Shares Outstanding	Altman Z-Score	Payout Ratio	Free Cash Flow / Net Income
OTC-AGTX	—	—	Fair	—	—	—	Weak	—	—	—	0.0%	—	-1.7x	-0.2x	—	801.339 K	1.154 M	30.6%	—	-20,225.2	—	22.3%